Skip to content
Review Open access

Beyond antibiotics: artificial intelligence–enabled anti-infective ecosystems for next-generation precision therapeutics against antimicrobial resistance

Aug 2026 · Frontiers in Cellular and Infection Microbiology · Vol 16 · 0 citations · 58 references
Medicine

TL;DR

The Intelligent Anti-Infective Ecosystem (IAIE) is proposed as a conceptual systems-level framework that computationally integrates multimodal diagnostics, pathogen genomics, microbiome profiling, AI-assisted decision support, programmable precision therapeutics, ecological monitoring, and longitudinal clinical feedback within a continuously learning dynamically optimized workflow.

Abstract

The rapid global expansion of antimicrobial resistance (AMR) threatens to undermine decades of progress in infectious disease management and highlights the limitations of conventional antibiotic-centered therapeutic strategies. Although emerging technologies—including antimicrobial peptides, bacteriophage therapy, CRISPR-based antimicrobials, microbiome therapeutics, anti-virulence approaches, nanotechnology-enabled drug delivery, and artificial intelligence (AI)—have individually demonstrated considerable promise, they are predominantly being developed as independent interventions rather than as coordinated components of an integrated therapeutic strategy. This Perspective proposes the Intelligent Anti-Infective Ecosystem (IAIE) as a conceptual systems-level framework that computationally integrates multimodal diagnostics, pathogen genomics, microbiome profiling, AI-assisted decision support, programmable precision therapeutics, ecological monitoring, and longitudinal clinical feedback within a continuously learning dynamically optimized workflow. Unlike existing paradigms that primarily optimize individual technologies or therapeutic decisions, IAIE emphasizes closed-loop coordination among complementary antimicrobial approaches to support precision-guided infection management while preserving microbiome integrity and mitigating resistance selection pressure. We further outline the core components, operational principles, translational challenges, and technology readiness of the major therapeutic platforms that could contribute to such an ecosystem, while distinguishing clinically established interventions from emerging experimental strategies. Importantly, IAIE should be interpreted as a prospective conceptual architecture rather than an existing clinical platform. Its proposed clinical value remains to be established through sequential computational, preclinical, and prospective clinical investigations using standardized microbiological, ecological, and patient-centered outcome measures. By framing antimicrobial innovation within an responsive systems perspective, IAIE provides a roadmap for future multidisciplinary research aimed at integrating artificial intelligence and systems microbiology to enable sustainable management of antimicrobial resistance.

Read PDF

Similar papers

Review Aug 2026

Precision Medicine in Combating Antimicrobial Resistance: A Comprehensive Review.

This review concludes that while precision medicine is not a standalone solution, its successful implementation will depend on coordinated integration of diagnostics, host factors, computational tools, pharmacological optimization, and stewardship strategies to improve patient outcomes while preserving the long-term ef...

Lamarana Jallow, Henry Hodosika, Ousman Bajinka · 0 citations
Review Open access Sep 2026

Antimicrobial peptides in the era of resistance: integrating AI-driven design, host-microbe interactions, and nanotechnological delivery

This review synthesizes recent advances in AMP research, focusing on their structural diversity, mechanistic interactions with microbial membranes, and immunomodulatory roles in shaping host-microbe dynamics, and establishes a framework for overcoming current limitations.

Zhu-Yu Hua, Xu Xia, Khan Qaisar et al. · 0 citations
Review Open access Aug 2026

The Therapeutic Potential of Phages in Multi-Drug Resistance Infections and Future Directions

This review systematically analyzes major challenges restricting clinical application, such as standardized production, quality control, pharmacokinetic characterization, rapid pathogen identification, and regulatory adaptation, as well as the limited performance of fixed phage cocktails against genetically heterogeneo...

Sheng-Ting Zhang, Hui-Li Tao, Sha Zhao et al. · 0 citations
Review Open access Sep 2026

Host-directed therapeutics against antimicrobial-resistant bacterial infections: emerging roles of multi-omics and systems biology

The rapid emergence and global dissemination of antimicrobial resistance (AMR), coupled with the limited development of new antimicrobial agents, have intensified concerns regarding a major global public health crisis. Although antibiotic resistance is primarily driven by microbial mechanisms, host immune and inflammat...

Sarmistha Saha, N. Sachivkina, Oksana Gizinger et al. · 0 citations
Review Open access Sep 2026

Antibiotic-Free Strategies for Managing Antimicrobial-Resistant Infections

This review provides a comprehensive assessment of emerging antibiotic-free strategies to guide the development of next-generation antimicrobial solutions that reduce reliance on antibiotics and mitigate AMR in clinical and healthcare settings.

P. Ganguly, Elena A. Jones, P. Giannoudis et al. · 0 citations
Review Sep 2026

Non-antibiotic therapeutic approaches for antimicrobial resistance: current evidence and future directions.

This review summarizes the current evidence on non-antibiotic therapeutics including bacteriophages, antimicrobial peptides, anti-virulence agents, monoclonal antibodies, microbiome-based therapies, CRISPR-Cas systems, nanoparticles, photodynamic therapy, repurposed non-antibiotic drugs and combination strategies.

Bharath Kumar Ganesan, A. Mishra, Debasish Hota et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.